Treatment with cabozantinib gives patients with advanced renal cell carcinoma significantly more time without disease progression and toxicity relative to treatment with sunitinib, CABOSUN trial data show.
Cisplatin-ineligible patients with locally advanced or high-risk urothelial carcinoma could benefit from neoadjuvant treatment with a PD-1/PD-L1 inhibitor in combination with a CTLA-4 inhibitor, show two phase 1 studies published in Nature Medicine.
A prognostic model based on eight DNA repair-related genes may help identify women with breast cancer who are at high risk for death, Chinese researchers report.
Older patients with non-small-cell lung cancer who have not progressed on platinum-based doublet therapy do not gain an overall survival advantage if treated with switch maintenance therapy rather than observation, study findings show.